All In Biotech

Drug Trial Radar · NCT03654105

Screening and Multiple Intervention on Lung Epidemics

Multifactorial Intervention of Primary Prevention in High Risk Subjects: a Randomized Trial

Last checked: Nov 20, 2026Latest source record: Mar 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingRandomized with 2,000 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

2,000

Planned (sponsor's estimate)

Start

Jul 23, 2019

Primary completion

Dec 31, 2024

Study completion Dec 31, 2026

Sponsor

Lead sponsor
Fondazione IRCCS Istituto Nazionale dei Tumori, MilanoAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Istituto Di Ricerche Farmacologiche Mario Negri
First posted
Aug 31, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Factorial
Masking
None
Primary purpose
Prevention
FDA-regulated drug
No
Who can join
All sexes, from 55 years, up to 75 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This prospective randomized pilot trial will evaluate a multiple intervention program of prevention in lifelong smokers aiming at reduction of chronic inflammation status through treatment with low-dose acetylsalicylic acid (ASA), smoking cessation with cytisine, targeted modification of diet and physical activity, in addition to early diagnosis with annual ultra low-dose spiral computed tomography (LDCT).

Conditions

  • Inflammation
  • Smoking Cessation
  • Diet Modification
  • Physical Activity
  • Lung Cancer

Interventions

  • CytisineDrug

    Cytisine administration will be randomized 1:1 in standard (40 days)and prolonged treatment (84 days). Subjects will be educated on how to take the product and informed about possible adverse effects.

  • Acetylsalicylic acidDrug

    The treatment will consist of Acetylsalicylic acid at 100mg once a day

  • Diet Modification and Physical Activity IncreaseOther

    It will be proposed: 1. an optimal diet with the aim of favoring control of weight, abdominal fat and adequate nutritional status without increasing the levels of IGF-I and inflammatory factors or glycemic peaks, with periodic verification of the results 2. a regular and sustainable physical activity program with periodic verification of the results.

  • early lung cancer detectionDiagnostic test

    standard treatment for early lung cancer detection with ultra low dose CT

  • spirometry with CO testDiagnostic test

    spirometry with CO test

  • anthropometic data collectionOther

    anthropometic data collection

  • blood testOther

    blood test to assess the metabolic and inflammatory profile

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in chronic inflammatory statusTime frame: 1 year

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Fondazione IRCCS Istituto Nazionale dei Tumori

    Milan, Italy

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.